FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912986738> ?p ?o ?g. }

• W2912986738 endingPage "1267" @default.
• W2912986738 startingPage "1251" @default.
• W2912986738 abstract "BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH) is an incurable, incapacitating disorder resulting from increased pulmonary vascular resistance, pulmonary arterial remodeling and right ventricular failure. In pre-clinical models, combination of a phosphodiesterase 5 inhibitor (PDE5i) with a neprilysin inhibitor augments natriuretic peptide bioactivity, promotes cyclic GMP signaling, and reverses the structural and hemodynamic deficits that characterize PAH. Herein, we conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of repurposing the neprilysin inhibitor, racecadotril, in PAH. EXPERIMENTAL APPROACH: 21 PAH patients stable on PDE5i therapy were recruited. Acute hemodynamic and biochemical changes following a single dose of racecadotril or matching placebo were determined; this was followed by a 14 day safety and efficacy evaluation. The primary endpoint in both steps was circulating atrial natriuretic peptide (ANP) concentration (Δmax ), with secondary outcomes including pulmonary and systemic hemodynamics plus mechanistic biomarkers. KEY RESULTS: Acute administration of racecadotril (100mg) resulted in a 79% (95%CI, +6,+203) increase in the plasma ANP concentration and a 106% (+28,+229) increase in plasma cyclic GMP levels, with a concomitant 14% (-24,-3) fall in pulmonary vascular resistance. Racecadotril (100mg; tid) treatment for 14 days resulted in a 19% (-18,+72) rise in plasma ANP concentration. Neither acute (-16%,-28,+1) nor chronic (-4%, -21,+16) administration of racecadotril resulted in a significant drop in MABP or any serious adverse effects. CONCLUSIONS AND IMPLICATIONS: This Phase IIa evaluation provides proof-of-principle evidence that neprilysin inhibitors may have therapeutic utility in PAH and warrants a larger-scale prospective trial." @default.
• W2912986738 created "2019-02-21" @default.
• W2912986738 creator A5007819070 @default.
• W2912986738 creator A5009373315 @default.
• W2912986738 creator A5010488895 @default.
• W2912986738 creator A5022354423 @default.
• W2912986738 creator A5034519980 @default.
• W2912986738 creator A5050394347 @default.
• W2912986738 creator A5050668011 @default.
• W2912986738 creator A5051227252 @default.
• W2912986738 creator A5063653314 @default.
• W2912986738 creator A5066036690 @default.
• W2912986738 creator A5067573670 @default.
• W2912986738 creator A5067577703 @default.
• W2912986738 creator A5070964883 @default.
• W2912986738 creator A5081153233 @default.
• W2912986738 creator A5091701527 @default.
• W2912986738 date "2019-03-31" @default.
• W2912986738 modified "2023-10-16" @default.
• W2912986738 title "Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial" @default.
• W2912986738 cites W1545907965 @default.
• W2912986738 cites W1584494699 @default.
• W2912986738 cites W1759599154 @default.
• W2912986738 cites W1836315310 @default.
• W2912986738 cites W1964952529 @default.
• W2912986738 cites W1970026767 @default.
• W2912986738 cites W1976038658 @default.
• W2912986738 cites W1978734517 @default.
• W2912986738 cites W1981484351 @default.
• W2912986738 cites W1990958786 @default.
• W2912986738 cites W1992989380 @default.
• W2912986738 cites W2021894572 @default.
• W2912986738 cites W2024667090 @default.
• W2912986738 cites W2024857020 @default.
• W2912986738 cites W2025252445 @default.
• W2912986738 cites W2027630718 @default.
• W2912986738 cites W2032126076 @default.
• W2912986738 cites W2033379487 @default.
• W2912986738 cites W2037090738 @default.
• W2912986738 cites W2040562793 @default.
• W2912986738 cites W2053926785 @default.
• W2912986738 cites W2072859275 @default.
• W2912986738 cites W2090878184 @default.
• W2912986738 cites W2092237225 @default.
• W2912986738 cites W2093943199 @default.
• W2912986738 cites W2097123331 @default.
• W2912986738 cites W2097981541 @default.
• W2912986738 cites W2102994334 @default.
• W2912986738 cites W2103804424 @default.
• W2912986738 cites W2107011819 @default.
• W2912986738 cites W2110202498 @default.
• W2912986738 cites W2113698123 @default.
• W2912986738 cites W2121376498 @default.
• W2912986738 cites W2126939785 @default.
• W2912986738 cites W2132418248 @default.
• W2912986738 cites W2138649273 @default.
• W2912986738 cites W2144354658 @default.
• W2912986738 cites W2149688277 @default.
• W2912986738 cites W2253226022 @default.
• W2912986738 cites W2298790217 @default.
• W2912986738 cites W2317369439 @default.
• W2912986738 cites W2338761443 @default.
• W2912986738 cites W2765684626 @default.
• W2912986738 cites W2766119667 @default.
• W2912986738 cites W2766306821 @default.
• W2912986738 cites W2771328536 @default.
• W2912986738 doi "https://doi.org/10.1111/bph.14621" @default.
• W2912986738 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7651846" @default.
• W2912986738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30761523" @default.
• W2912986738 hasPublicationYear "2019" @default.
• W2912986738 type Work @default.
• W2912986738 sameAs 2912986738 @default.
• W2912986738 citedByCount "18" @default.
• W2912986738 countsByYear W29129867382019 @default.
• W2912986738 countsByYear W29129867382020 @default.
• W2912986738 countsByYear W29129867382021 @default.
• W2912986738 countsByYear W29129867382022 @default.
• W2912986738 countsByYear W29129867382023 @default.
• W2912986738 crossrefType "journal-article" @default.
• W2912986738 hasAuthorship W2912986738A5007819070 @default.
• W2912986738 hasAuthorship W2912986738A5009373315 @default.
• W2912986738 hasAuthorship W2912986738A5010488895 @default.
• W2912986738 hasAuthorship W2912986738A5022354423 @default.
• W2912986738 hasAuthorship W2912986738A5034519980 @default.
• W2912986738 hasAuthorship W2912986738A5050394347 @default.
• W2912986738 hasAuthorship W2912986738A5050668011 @default.
• W2912986738 hasAuthorship W2912986738A5051227252 @default.
• W2912986738 hasAuthorship W2912986738A5063653314 @default.
• W2912986738 hasAuthorship W2912986738A5066036690 @default.
• W2912986738 hasAuthorship W2912986738A5067573670 @default.
• W2912986738 hasAuthorship W2912986738A5067577703 @default.
• W2912986738 hasAuthorship W2912986738A5070964883 @default.
• W2912986738 hasAuthorship W2912986738A5081153233 @default.
• W2912986738 hasAuthorship W2912986738A5091701527 @default.
• W2912986738 hasBestOaLocation W29129867381 @default.
• W2912986738 hasConcept C104826730 @default.
• W2912986738 hasConcept C126322002 @default.
• W2912986738 hasConcept C142724271 @default.

• next